ESSA Pharma Inc. announced an amendment to its Business Combination Agreement with XenoTherapeutics Inc., backed by XOMA Royalty Corporation. Under the revised terms, ESSA shareholders are now expected to receive approximately US$0.12 per common share in cash at closing, exclusive of the approximately US$1.69 previously distributed.
The total estimated aggregate distribution, which was originally approximately US$1.91 per common share, has been adjusted. Additionally, each shareholder will receive one non-transferable contingent value right (CVR) per common share, now representing the right to receive up to approximately US$0.14 per CVR. This CVR payment, totaling up to US$6.7 million in aggregate, is contingent on certain liabilities.
This amendment reflects adjustments made in light of potential liabilities, associated expenses, and updated estimates of the company's cash balance at closing. The special meeting to approve the amended agreement has been further adjourned to October 3, 2025, with a new court hearing date for approval set for October 7, 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.